Delivery Order SPE2DB24D2208-SPE2DB25FHJBD
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 12, 2025, for the supply of Multaq 400 mg tablets (60-count units) valued at $11,985.90. This non-set-aside, competitively awarded contract utilizes firm fixed pricing and is classified as a delivery order, with an ultimate completion date of August 13, 2025. The pharmaceutical product will be delivered to the Conshohocken, Pennsylvania location, where AmerisourceBergen maintains its corporate...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on August 8, 2025, for the supply of Multaq 400 mg tablets in quantities of 60 units. This firm fixed-price delivery order, valued at $5,068.62, is set to be completed by August 11, 2025, and will be performed at AmerisourceBergen's facility in Conshohocken, Pennsylvania. The award represents a non-competitive delivery order issued under AmerisourceBergen's existing contract vehicle with DLA, reflecting...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on August 7, 2025, for the supply of Multaq 400 mg tablets (60-count packages) valued at $2,515.53. This firm fixed-price delivery order is set to conclude on August 8, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The award represents a non-competitive delivery order issued under an existing contract vehicle, reflecting the company's...
- The Defense Logistics Agency awarded a delivery order valued at $1,219.02 to AmerisourceBergen Drug Corp on August 7, 2025, for the supply of Multaq 400 mg tablets in a 60-count package. This is a firm fixed-price delivery order with no set-aside designation, reflecting a competitively awarded contract. The product will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, with a completion date of August 8, 2025. As a child contract under a larger vehicle,...
- The Defense Logistics Agency Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on August 1, 2025, for the supply of Multaq 400 mg tablets (60-count units) under a firm fixed price contract. The award, valued at $14,666.83, is scheduled for completion by August 4, 2025, and represents a competitively awarded non-set-aside procurement. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, serves as a critical pharmaceutical distributor for federal medical...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 26, 2025, for the supply of Multaq 400 mg tablets (60-count packages) valued at $92,596.99. This firm fixed-price delivery order represents a competitive award with no set-aside designation and has an ultimate completion date of August 27, 2025. The contract will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen...
- The Defense Logistics Agency awarded a $3,254.50 delivery order to AmerisourceBergen Drug Corp on September 4, 2025, for the supply of Multaq 400 mg tablets (60-count units). This is a firm fixed price, competitively awarded contract with no set-aside designation and an ultimate completion date of September 5, 2025. The contract is being performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is executed under AmerisourceBergen's Indefinite...
- The Defense Logistics Agency's Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on August 27, 2025, for the supply of Multaq 400 mg tablets (60-count units) with a contract ceiling value of $11,265.36. This firm fixed-price delivery order, which carries an ultimate completion date of August 28, 2025, represents a non-competitive set-aside award issued under AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical. The...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 12, 2025, for the supply of Multaq 400 mg tablets (60-count units) valued at $24,960.51 with firm fixed pricing. This competitively awarded, non-set-aside contract is scheduled for completion by September 15, 2025, with performance of work occurring at AmerisourceBergen's facility in Conshohocken, Pennsylvania. The delivery order represents a child contract action under AmerisourceBergen's...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 18, 2025, for the supply of Multaq 400 mg tablets (60-count units) with a ceiling value of $8,201.13. This firm fixed-price delivery order, which is scheduled for completion by August 19, 2025, represents a competitively awarded contract with no set-aside designation. The order will be fulfilled from AmerisourceBergen's Conshohocken, Pennsylvania facility, where the company maintains its corporate...
- SPE2DB24D2208Indefinite Delivery Contract
- SPE2DB24D2208-SPE2DB25FHJBDDelivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 14, 2025, for the supply of Multaq 400 mg tablets (60-count units) valued at $7,902.75 under a firm fixed-price contract. This non-set-aside delivery order represents a routine pharmaceutical procurement supporting federal medical supply needs, with an ultimate completion date of August 15, 2025. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a $999,999,999.00 comprehensive pharmaceutical prime vendor agreement running through December 2026. As a major pharmaceutical distributor and critical federal healthcare vendor, AmerisourceBergen supplies a broad portfolio of medications and medical supplies to support military and veteran healthcare systems, including specialty pharmaceuticals, vaccines, and medical devices across multiple therapeutic domains. The company's federal procurement activities demonstrate consistent capability to meet DLA requirements through competitive procurement processes, supporting military healthcare programs and defense health initiatives globally.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $7.9k | 8/14/25 |